Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
Titel:
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
Auteur:
Wu, Yi-Long Saijo, Nagahiro Thongprasert, Sumitra Yang, J. C.-H. Han, Baohui Margono, Benjamin Chewaskulyong, Busayamas Sunpaweravong, Patrapim Ohe, Yuichiro Ichinose, Yukito Yang, Jin-Ji Mok, Tony S.K. Young, Helen Haddad, Vincent Rukazenkov, Yuri Fukuoka, Masahiro